Resources Investment Advisors LLC. Sells 490 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Resources Investment Advisors LLC. lowered its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 7.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,992 shares of the biopharmaceutical company’s stock after selling 490 shares during the quarter. Resources Investment Advisors LLC.’s holdings in Halozyme Therapeutics were worth $229,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of HALO. CWM LLC lifted its holdings in Halozyme Therapeutics by 123.2% during the first quarter. CWM LLC now owns 848 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 468 shares during the period. Belpointe Asset Management LLC purchased a new stake in Halozyme Therapeutics during the fourth quarter worth $50,000. Harbour Investments Inc. purchased a new stake in Halozyme Therapeutics during the fourth quarter worth $51,000. Quadrant Capital Group LLC lifted its holdings in Halozyme Therapeutics by 111.5% during the fourth quarter. Quadrant Capital Group LLC now owns 960 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 506 shares during the period. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Halozyme Therapeutics during the fourth quarter worth $57,000. Hedge funds and other institutional investors own 92.93% of the company’s stock.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $42.41, for a total value of $424,100.00. Following the completion of the transaction, the senior vice president now directly owns 151,911 shares of the company’s stock, valued at $6,442,545.51. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 80,000 shares of company stock valued at $3,345,700 over the last quarter. 2.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently commented on HALO. The Goldman Sachs Group lowered Halozyme Therapeutics from a “buy” rating to a “neutral” rating and increased their price objective for the company from $43.00 to $45.00 in a report on Monday, July 24th. Piper Sandler increased their price objective on Halozyme Therapeutics from $46.00 to $48.00 in a report on Wednesday, August 9th. TheStreet upgraded Halozyme Therapeutics from a “c+” rating to a “b” rating in a report on Tuesday, August 8th. Morgan Stanley increased their price objective on Halozyme Therapeutics from $60.00 to $61.00 and gave the company an “overweight” rating in a report on Thursday, August 10th. Finally, StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, August 16th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $54.27.

Halozyme Therapeutics Trading Up 0.7 %

Halozyme Therapeutics stock opened at $42.24 on Friday. The company has a quick ratio of 5.44, a current ratio of 6.58 and a debt-to-equity ratio of 9.91. Halozyme Therapeutics, Inc. has a 52 week low of $29.85 and a 52 week high of $59.46. The company has a market capitalization of $5.57 billion, a price-to-earnings ratio of 24.70, a price-to-earnings-growth ratio of 0.64 and a beta of 1.24. The stock has a 50-day moving average price of $39.95 and a 200 day moving average price of $38.79.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.